Development of cultured Plasmodium falciparum blood-stage malaria cell banks for early phase in vivo clinical trial assessment of anti-malaria drugs and vaccines.

Abstract

BACKGROUND:

The ability to undertake controlled human malaria infection (CHMI) studies for preliminary evaluation of malaria vaccine candidates and anti-malaria drug efficacy has been limited by the need for access to sporozoite infected mosquitoes, aseptic, purified, cryopreserved sporozoites or blood-stage malaria parasites derived ex vivo from malaria infected individuals. Three different strategies are described for the manufacture of clinical grade cultured malaria cell banks suitable for use in CHMI studies.

METHODS:

Good Manufacturing Practices (GMP)-grade Plasmodium falciparum NF54, clinically isolated 3D7, and research-grade P. falciparum 7G8 blood-stage malaria parasites were cultured separately in GMP-compliant facilities using screened blood components and then cryopreserved to produce three P. falciparum blood-stage malaria cell banks. These cell banks were evaluated according to specific criteria (parasitaemia, identity, viability, sterility, presence of endotoxin, presence of mycoplasma or other viral agents and in vitro anti-malarial drug sensitivity of the cell bank malaria parasites) to ensure they met the criteria to permit product release according to GMP requirements.

RESULTS:

The P. falciparum NF54, 3D7 and 7G8 cell banks consisted of >78% ring stage parasites with a ring stage parasitaemia of >1.4%. Parasites were viable in vitro following thawing. The cell banks were free from contamination with bacteria, mycoplasma and a broad panel of viruses. The P. falciparum NF54, 3D7 and 7G8 parasites exhibited differential anti-malarial drug susceptibilities. The P. falciparum NF54 and 3D7 parasites were susceptible to all anti-malaria compounds tested, whereas the P. falciparum 7G8 parasites were resistant/had decreased susceptibility to four compounds. Following testing, all defined release criteria were met and the P. falciparum cell banks were deemed suitable for release. Ethical approval has been obtained for administration to human volunteers.

CONCLUSIONS:

The production of cultured P. falciparum blood-stage malaria cell banks represents a suitable approach for the generation of material suitable for CHMI studies. A key feature of this culture-based approach is the ability to take research-grade material through to a product suitable for administration in clinical trials.

• Authors: Danielle I Stanisic, Xue Q Liu, Sai Lata De, Michael R Batzloff, Tanya Forbes, Christopher B Davis, Silvana Sekuloski, Marina Chavchich, Wendy Chung, Katharine Trenholme, James S McCarthy, Tao Li, B Kim Lee Sim, Stephen L Hoffman, Michael F Good
• Journal: Malaria journal (Malar J) Vol. 14 Pg. 143 (Apr 07 2015) ISSN: 1475-2875 [Electronic] England
• PMID: 25890156 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Antimalarials
• Malaria Vaccines

Topics

• Animals
• Antimalarials (pharmacology, therapeutic use)
• Biological Specimen Banks
• Clinical Trials as Topic
• Humans
• Malaria (drug therapy)
• Malaria Vaccines (administration & dosage, immunology)
• Plasmodium falciparum (drug effects, growth & development, immunology)
• Sporozoites (drug effects, growth & development, immunology)